Board of Directors
Our Directors bring a wealth of business, financial and industry experience, having worked for institutions such as Amersham, Citigroup, Deloitte, Dompe Farmaceutici, EQT, LSP, Sanofi-Aventis and SmithKline Beecham as well as managing and owning some of the largest Hedge Funds globally. They are committed to support the short- and long-term value creation at Engitix by maximising the clinical and commercial potential of our therapeutics pipeline.
Eduardo was appointed as Chairman of the Board in November 2020.
He has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of CEO at Nordic Nanovector, TiGenix and Cellerix. As CEO at TiGenix, he oversaw several financing rounds, the company’s IPO on NASDAQ, and its eventual acquisition by Takeda.
Earlier in his career, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham.
He is currently Chairman of the Board at Vivet Therapeutics and a Board Member at Sutura Therapeutics.
Eduardo was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018, and was also member of the Executive Committee of Alliance for Regenerative Medicine. He holds a degree in Business Administration and an MBA from INSEAD.
Chief Executive Officer and Co-Founder
Professor Giuseppe Mazza co-founded Engitix and has served as Chief Executive Officer (CEO) since the Company’s formation in 2016.
Engitix was established to build on and commercialise Giuseppe’s pioneering research which resulted in a proprietary human extracellular matrix ECM drug discovery platform. His foundational/initial research was carried out in the laboratory of co-founder, Professor Massimo Pinzani at the Institute for Liver and Digestive Health (ILDH), Division of Medicine, University College London (UCL).
As CEO, Giuseppe has led the company through significant growth including several rounds of financing and secured significant partnerships with Dompei, Takeda and Morphic, as well as establishing new cutting-edge bespoke laboratories and offices at WestWorks, White Park, London.
Previously, Giuseppe was a Post-Doctoral Fellow at the UCL ILDH, where he was also responsible for operating the Tissue Engineering and Regenerative Medicine Laboratory. He received his PhD in Tissue Engineering and Organ Regeneration from UCL. He still maintains an affiliation with UCL as Honorary Associate Professor. Giuseppe also served as a Director R&D at Promethera Bioscience from 2015 to 2017.
He has been involved in several international healthcare organizations, including serving on the Steering Committee of the non-profit European Haemophilia Consortium (EHC). In 2011, he founded the healthcare charity Associazione Icore ONLUS, where he served as President for six years.
Mike Platt is the co-founder and CEO of BlueCrest Capital Management, which he started in late 2000 after nearly a decade at JP Morgan.
Mike built BlueCrest into one of the world's largest hedge fund firms; at its peak, it managed more than $35 billion in assets.
In 2015 he returned outside investors' money, remaking BlueCrest into a family office. The firm has flourished since then, generating a 95% net return in 2020 after returns in the 50% range in 2016, 2017 and 2019.
Gianluca Rosetti is Director of Strategic Planning and Business Development at Dompé farmaceutici. He joined Engitix’s Board of Directors in January 2022, following the closing of the collaboration and investment agreement with Dompé farmaceutici.
Gianluca has almost 10 years of experience in management consulting, with a specific focus in the Life Sciences. He has led strategic projects with several Fortune 500 companies that ranged from biopharmaceutical to medical devices and diagnostics.
He holds a Master Degree in Business Administration from the Università di Pavia, Italy.
Chief Financial Officer
David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018, having initially worked for the company as a consultant from 2016.
David has 30 years' experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.
David is an experienced executive having held the position of CEO at MerLion Pharmaceuticals from 2013 to 2018, before which he was CFO from 2007.
During his career, David has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.
David is a chartered accountant and holds a MA in Geography from the University of Cambridge.
Stephen Brindle is an Investor Director at Engitix. Previously, he held the role of Chief Operating Officer (COO) at the Company for seven years.
Before joining Engitix, he spent 8 years as Managing Partner of Technikos LLP, a medical devices venture capital fund with a long-term commercial contract with Oxford University’s Biomedical Engineering department.
Before Technikos Mr Brindle spent a decade as an equity salesman latterly with Citigroup and Goldman Sachs. Between 1991 and 1997 he worked as a management consultant, latterly at Deloitte Consulting.
He holds a BSc in Economics from LSE.
Dr. Quaratino has over 25 years of experience in immunology research, clinical development at biotechnology and pharmaceutical companies, has served on multiple boards, and overseen research programs at leading academic institutions. Her scientific interest includes the understanding of pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
She is currently Chief Medical Officer at Georgiamune INC (USA), Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics and a non-executive director for Circio ASA (OSE: CRNA) (previously known as TargoVax) and Ichnos Sciences INC.
Prior to her transition to a portfolio career, Dr Quaratino was Chief Medical Officer for Kymab, a clinical-stage biopharmaceutical company with a focus on immune-mediated diseases and immuno-oncology therapeutics, acquired by Sanofi for more than $1.1 billion in April 2021. Previously, she held roles as Global Clinical Program Leader in Translational Clinical Oncology at Novartis, Senior Medical Director and Immunology Advisor at Merck Serono, and was Professor of Immunology at the University of Southampton.
Dr. Quaratino received her Medical Degree and Doctorate in Hematology-Oncology from the University of Palermo, and her Ph.D. in Immunology from Imperial College London.